2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1871

Identifying Pain Sites Highly Associated with the Fibromyalgia (FM) Phenotype
Abstract Number: 859

Identifying Pain Susceptibility Phenotypes in Those Free of Knee Pain with or at Risk for Knee Osteoarthritis and Their Relation to Developing Knee Pain
Abstract Number: 2946

Identifying Rapid Structural Disease Progression in Knee Osteoarthritis
Abstract Number: 1854

Identifying Vulnerable Patient Populations Based on Age and Physical Function on Clinical Outcomes Following Total Knee Arthroplasty
Abstract Number: 1857

If Mobile Advertising Is the Future, the Future Is Now: Productivity of Digital Ads By Terminology and Delivery Device.
Abstract Number: 2882

IgG Galactosylation Status Combined with MYOM2 SNP Precisely Predicts Anti-TNF Response in Ankylosing Spondylitis
Abstract Number: 74

IL-17 Blockade Attenuates Osteoblastic Activity and Differentiation in Ankylosing Spondylitis
Abstract Number: 659

IL-17 Producing T Cells and Its Dichotomy: A Mixed Response of the Innate and Acquired Immune System in Psoriatic Arthritis
Abstract Number: 975

IL-17A Induced Autophagy That the Proliferation of Rheumatoid Arthritis Fibroblast-like Synoviocytes through Down-Regulation of PI3K/AKT/mTOR Signaling Pathway
Abstract Number: 1896

IL-18 As a Diagnostic Biomarker, Differentiating Systemic JIA from Acute Leukaemia, Severe Bacterial Infections and Other Auto-Immune Disorders
Abstract Number: 2698

IL-21-mTOR Axis Blocks the Differentiation and Function of SLE Tregs Via Suppression of Autophagy
Abstract Number: 1576

IL-23 Promotes Fecal Microbiota Dysbiosis Associated with Susceptibility to Spondyloarthritis and Ileitis in ZAP-70 Mutant SKG Mice
Abstract Number: 34

IL-23 Regulates Development of Spontaneous Germinal Centers and Pathogenic Autoantibody Production in BXD2 Mice
Abstract Number: 78

IL-37 Is Associated with Increased Atherogenesis in Patients with Rheumatoid Arthritis
Abstract Number: 973

IL-6 and TNF-a Cooperate to Modulate the Cell Cycle of RA-Fibroblast-like Synoviocytes Via Cyclin Dependent Kinase Inhibitors

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].